Lumretuzumab

Lumretuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Roche.

History

Lumretuzumab was part of a collaboration between Roche and Genmab, a Danish biotechnology company. The drug was designed to target and bind to the HER3 (human epidermal growth factor receptor 3) protein, which is often overexpressed in certain types of cancer.

Clinical trials

In 2015, Roche initiated a phase I clinical trial for lumretuzumab. The trial was designed to evaluate the safety, tolerability, and efficacy of the drug in patients with advanced solid tumors. However, the results of the trial were not as promising as hoped, and Roche decided to discontinue the development of lumretuzumab in 2017.

Mechanism of action

Lumretuzumab works by binding to the HER3 protein on the surface of cancer cells. This binding inhibits the ability of the HER3 protein to send signals that promote cell growth and survival, thereby slowing or stopping the growth of the cancer.

See also

• Monoclonal antibodies
• Cancer treatment
• Clinical trial
• Roche
• Genmab